Theliatinib
Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively. (In Vivo) :Theliatinib (2-15 mg/kg; oral administration; daily; for 21 days; NOD-SCID mice; PDECX 1T0950 model) treatment demonstrates tumor regression of 75% at the end of study, and with a dose response.
Product Specifications
CAS Number
1353644-70-8
Purity
>98% (HPLC)
Solubility
DMSO:47 mg/mL (106.21 mM)
Smiles
[H][C@]12CCN (C) [C@@]1 ([H]) CN (C2) C (=O) Nc1cc2c (Nc3cccc (c3) C#C) ncnc2cc1OC
Molecular Formula
C25H26N6O2
Molecular Weight
442.5
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(3aR6aR) -N- (4- ((3-ethynylphenyl) amino) -7-methoxyquinazolin-6-yl) -1-methylhexahydropyrrolo[34-b]pyrrole-5 (1H) -carboxamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Lactobacillus salivarius Initiation-control protein yabA (LSL_1222)
Recombinant Lactobacillus salivarius Initiation-control protein yabA (LSL_1222)
Recombinant Lactobacillus salivarius Initiation-control protein yabA (LSL_1222)
Recombinant Lactobacillus salivarius Initiation-control protein yabA (LSL_1222)